Key Dates

Related Announcements

PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Issued by

National Cancer Institute (NCI)

Purpose

This Notice of Special Interest (NOSI) describes an opportunity for supplemental funding to grantees for studies that address patterns of tobacco and cannabis use as a target for cancer prevention and control. The goal of this initiative is to supplement existing awards to collect new data and/or analyze existing data.

Background

Tobacco use causes approximately 30% of cancer deaths in the United States. Recent population-level data indicate that as many as 30% of tobacco users may also regularly use cannabis. This pattern of tobacco and cannabis use or co-use (i.e., using both substances at the same time or within the same time frame, such as past week or month) likely has important implications for cancer prevention and control. For example, evidence suggests that initiating use of one substance increases the likelihood of using the other, particularly among youth. Other research suggests that cannabis use among current and former tobacco users can alter tobacco use behaviors (e.g., attempts to quit; relapse after quitting). However, the research is mixed and emerging; new tobacco and cannabis products continue to be developed and marketed, cannabis policies are at various stages of implementation, and the landscape of tobacco and cannabis use is changing. The measurement of behaviors (e.g., mode of use, frequency, initiation, cessation) and contextual factors (e.g., policy, environment) must be carefully considered when assessing patterns and correlates of use and co-use. Efforts to examine tobacco and cannabis use and co-use are needed to determine whether and how cannabis use influences tobacco initiation, use patterns, and cessation. Understanding these relationships is important to advance tobacco prevention and control and improve public health.

Research Objectives

The research objective of this NOSI is to examine patterns of tobacco and cannabis use. Studies should collect new and/or analyze existing data on patterns of tobacco and cannabis use in adults and/or youth, especially among unrepresented, underserved, and/or vulnerable groups (e.g., socioeconomically disadvantaged populations, cancer patients/survivors). Studies that examine behavioral and policy factors are also highly encouraged. Data from these supplements are expected to be broadly shared with the extramural research community.

Specific topics of interest include, but are not limited to:

• Understanding the prevalence and/or trajectory of a pattern of tobacco and cannabis use or co-use;
• Examining the mode and frequency of co-use, including any diversity in products used;
• Investigating whether cannabis use is considered in tobacco prevention and control interventions;
• Examination of environmental, media, advertising, marketing, and policy influences on initiation and regular use of tobacco and cannabis in adults and youth;
• Understanding potential interactions between tobacco- and cannabis-related policies and tobacco prevention and control;
• Investigating whether patterns of tobacco and cannabis use influence cancer risk.

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

• PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:

• Application Due Date: Submissions must be received by May 27, 2022, at 5:00 PM local time of applicant organization for FY 2022 funding.
• For funding consideration, applicants must include “NOT-CA-22-070” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
• Applicants should begin the supplement application abstract by stating “This application is being submitted in response to the Notice of Special Interest (NOSI) identified as “NOT-CA-22-070”.

Eligibility and Eligible Individuals (Program Director/Principal Investigator)

• Administrative supplement applications are limited to currently funded projects supported by NCI.
• Administrative supplement applications are limited to currently funded R01, R37, P01, and U01 projects supported by NCI. Requests for no-cost extensions on the parent grant to accommodate a supplement will not be permitted.
• PDs/PIs must hold an active award supported through NCI with sufficient time (minimum 1 year) left to complete the study proposed after the supplement has been awarded within the existing project period.
• The proposed project for supplemental funding is required to be within the scope of the parent award and be a logical extension of the original aims.
• For supplements to parent awards that include multiple PDs/PIs, the supplement may be requested by any or all of the PDs/PIs (in accordance with the existing leadership plan) and submitted by the awardee institution of the parent award.
• Application Due Date: All requests, regardless of the parent award funding mechanism, must be received by 5:00 PM local time on May 26, 2022, for possible funding in FY 2022. This NOSI will expire on May 27, 2022.

Budget

• The budget should not exceed $50,000 in total costs.

• • At least one full year on the parent grant must remain at the time of funding. The application budget is limited to 1 year only.
  • If an applicant anticipates a balance of 50% or more of the current total costs for the parent grant, please contact the scientific research contact prior to submitting an application.

• • Only one supplement application per grant will be accepted for consideration through this NOSI.
  • Requests must reflect the actual needs of the proposed project. Administrative supplements can be used to cover cost increases that are associated with achieving certain new research objective as long as the research objectives are within the original scope of the peer-reviewed and approved project (i.e., award), or the cost increases are for unanticipated expenses within the original scope of the project.

Requests

• Permitted for 1 year of support only; the earliest anticipated start date is September 1, 2022.
• For administrative supplements to grants and cooperative agreements, supplement requests must be submitted in accordance with the parent program announcement, PA-20-272. NOTE: Administrative supplement requests (application) for support of clinical trials will not be accepted and/or considered in response to this NOSI.
• Applicants should begin the supplement application abstract by stating “This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA-22-070.”
• Supplement requests should be submitted electronically.
• For funding consideration, applicants must include “NOT-CA-22-070” (without quotation marks) in the Agency Routing Identifier field (box 4b) of the SF424 R&R form. Applications without this information in box 4b will not be considered for this initiative.
• In order to facilitate efficient processing of the request applicants are strongly encouraged to notify the assigned NCI Program Official for the parent award that a request has been submitted in response to this NOSI.

Page limits – these sections have the following limits:

• Project Summary/Abstract: 30 lines of text
• Project Narrative: 3 sentences
• Research Strategy: 5 pages
• Biographical Sketch: for Senior/Key Personnel and Significant Contributors only

Review and Selection Process

• Does the administrative supplement reasonably allow for the proposed project to be completed, given the time and budget requested?
• Does the proposed project for supplemental funding fill an identified gap in the scientific literature that advances cancer research?
• Are the proposed activities relevant to the parent grant and original work scope?
• Does the applicant demonstrate satisfactory progress towards achieving the aims of the parent grant, as appropriate to the current stage of the project?
• Do the results from the proposed project have the potential to provide new evidence on patterns of tobacco and cannabis use that will provide a greater understanding of the prevention, treatment, and/or control of tobacco use?
• Does the proposed project appropriately justify the inclusion of unrepresented, underserved, and/or vulnerable populations?

Applicants are encouraged to discuss their application with the scientific/research contact listed in this NOSI prior to submission.

Inquiries

Please direct all inquiries to:

Joseph Ciccolo, Ph.D.
National Cancer Institute (NCI)
Telephone: 301-639-0943
Email: [email protected]